Contract manufacturer Lonza tempered its sales outlook for the rest of the year due in part to lower-than-expected growth in the services it provides to biotechs amid a slowdown in funding. Lonza on …
Read Full Story at source (may require registration)
Vancouver, BC, Jan. 23, 2025 (GLOBE NEWSWIRE) -- American Tungsten Corp. (CSE:TUNG) (OTCQB:DEMRF) (FSE:RK9) (“American Tungsten” or the “Company”) is...
Private placement of $6.5 million with a global investor and entrepreneur, Mr. Alejandro Weinstein, who will join Pluri’s Board of...
- U.S. FDA 510(k) filing of next-generation Novasight system targeted for H2 2025 with U.S. commercial launch planned for early...
Key Highlights: Revenue and Gross Profit Growth with Reduced Losses: GURU achieved a 3.3% increase in net revenue to $30.2...
Market-leading clinical software to join the comprehensive Cority Health CloudTORONTO, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Cority, the global leader...
Tin mineralization is hosted in an extensive intrusion breccia unit (TIB) that is approximately 750m long by 450m wide and...
